Project

General

Profile

Wiki » History » Version 65

Jason Bobe, 03/09/2010 11:16 PM

1 36 Jason Bobe
 = Genotype + Environment = Trait Evidence (GET-E) Database = 
2 1 Jason Bobe
3 38 Jason Bobe
The '''GET-E''' project was started by Abraham Rosenbaum, Joe Thakuria, Xiaodi Wu and Alexander Wait Zaranek to help the [http://personalgenomes.org Personal Genome Project], the clinical genetics community, and, the general public interpret individual genomes.  The database is closely integrated with [wiki:Trait-o-matic].
4 1 Jason Bobe
5
You can find the PGP production server at:
6
 * http://evidence.personalgenomes.org
7
8
A development sandbox can be found at: 
9
 * http://evidence-dev.personalgenomes.org
10
11 37 Jason Bobe
Many contributors helped make '''GET-E''' possible. You can find specific contributions at: 
12 1 Jason Bobe
 * http://evidence.personalgenomes.org/editors
13
14 38 Jason Bobe
Please help the project by editing the database, writing software tools that use the database (eg. Trait-o-matic/AETAS) or by making suggestions on the wiki!  
15 1 Jason Bobe
16 28 Jason Bobe
 == Field Descriptions and Editing Guidelines ==
17 19 Jason Bobe
 === Short Summary === 
18
 * free text providing a one line summary of clinical action to be undertaken given this variant (possibly modified by known phenotypes). 
19
20 64 Jason Bobe
 === Variant Evidence === 
21 63 Jason Bobe
Each of these fields is a sliding scale of 0-5 where 0 represents no evidence and 5 strong evidence within the given category. Where the data is not entered the default is N/A. When Genetests and/or the literature correlate this variant with a number of phenotypes the impact should be reported for the most extreme condition
22 58 Jason Bobe
 a. Computational: One star for each consistent prediction and one star subtracted for conflicting results from:
23 26 Jason Bobe
  i. evolutionary conservation (minimum of three species)
24
  i. presence in active domain 
25 27 Jason Bobe
  i. SIFT 
26
  i. !PolyPhen 
27 44 Jason Bobe
  i. NBLOSUM >= 2
28 27 Jason Bobe
  i. GVGD
29 23 Jason Bobe
  i. Other variants in this gene cause similar disease 
30
  i. etc... 
31 58 Jason Bobe
 a. Functional: One star for each experiment supporting the result, and penalize one star for conflicting results from: 
32 23 Jason Bobe
  i. enzyme extracts 
33
  i. cell lines  
34
  i. animal models
35
  i. etc... 
36 50 Jason Bobe
 a. Case/Control: A combination of odds ratio and significance test (currently using Fisher's Exact Test). For protective alleles, use inverse OR = 1 / OR. Do not count related individuals, count probands -- ie. one per family
37 40 Jason Bobe
  i. 0 stars if no higher ranking is allowed
38 41 Jason Bobe
  i. 1 star if OR>1 and significance <= 0.1
39
  i. 2 stars if OR>=1.5 and significance <= 0.05
40 45 Jason Bobe
  i. 3 stars if OR>=2 and significance <= 0.025
41
  i. 4 stars if OR>=3 and significance <= 0.01
42
  i. 5 stars if OR>=5 and significance <= 0.0001
43 24 Jason Bobe
 a. Familial Disease Segregation
44 25 Jason Bobe
  i. 0 stars for no segregation (LOD < -2)
45 24 Jason Bobe
  i. 1 star if segregation exists in one family pedigree
46
  i. 2 stars for segregation in more than one family with some conflicting information (e.g. asymptomatic carrier of young age or possibility of second causative mutation)
47
  i. 3 stars for more than one family no conflicting information
48
  i. 4 stars for LOD > 2
49 1 Jason Bobe
  i. 5 stars for LOD > 3
50 63 Jason Bobe
51 64 Jason Bobe
 === Clinical Importance ===
52 63 Jason Bobe
As with the Variant Quality section, each of these fields is a sliding scale of 0-5. These two categories are not applicable for benign and protective variants.
53
54
 a. Disease severity: downgraded according to disease penetrance (eg. Crohn's disease would be moderate or severe, but "increased susceptibility" is only increased the chances by ~.15% and so is called mild). For pharmacogenetic variants this is the severity of using the wrong drug/dosage.
55 51 Jason Bobe
  i. 0 stars for benign
56 60 Jason Bobe
  i. 1 star for very low expectation of having symptoms for this genotype, very low penetrance (eg. Susceptibility to crohn's with OR = 4.5, causing a ~.2% risk of Crohn's)
57
  i. 2 stars for mild effect on quality of life or unlikely to be symptomatic (Cystinuria)
58
  i. 3 stars for moderate effect on quality of life (eg. Familial mediterranean fever)
59
  i. 4 stars for severe effect: causes serious disability or reduces life expectancy (eg. Sickle-cell, Stargardt's disease)
60
  i. 5 stars for very severe effect: early lethal (eg. Familial adenomatous polypopsis, adrenoleukodystrophy)
61 51 Jason Bobe
 a. Treatability:
62
  i. 0 stars for no clinical evidence supporting intervention (eg. PAF acetylhydrolase deficiency)
63
  i. 1 star for uncurable: treatment only to alleviate symptoms (eg. adrenoleukodystrophy)
64 59 Jason Bobe
  i. 2 stars for potentially treatable: Treatment is in development or controversial
65
  i. 3 stars for treatable but a significant fraction do not require treatment (Cystinuria)
66 1 Jason Bobe
  i. 4 stars for treatable: Standard treatment reduces the amount of mortality/morbidity but does not eliminate it (eg. Sickle-cell disease)
67 54 Jason Bobe
  i. 5 stars for extremely treatable: Well-established treatment essentially eliminates the effect of the disease (eg. PKU)
68 1 Jason Bobe
69 47 Jason Bobe
 === Impact ===
70 64 Jason Bobe
This is filled in as one of the following:
71 32 Jason Bobe
 a. Pathogenic: Causative for disease. 
72
 a. Benign: No clinically significant phenotype. 
73 1 Jason Bobe
 a. Protective: Protective from disease.
74
 a. Pharmacogenetic: Clinically significant phenotype in the presence of a pharmacological agent.    
75
 a. NR: Not reviewed.
76
77 64 Jason Bobe
In addition to these categories, up to two qualifiers will be added automatically according to the variant quality scores. The first, "evidence", is based on the four "Variant Evidence" categories. The second, "importance", is based on the two "Clinical Importance" categories (not applicable for benign and protective categories).
78 1 Jason Bobe
79 64 Jason Bobe
An example for "pathogenic" follows:
80
|| - ||'''low evidence'''||'''moderate evidence'''||'''high evidence'''
81
||'''low importance'''|| uncertain pathogenic || likely pathogenic || pathogenic
82
||'''moderate importance'''|| uncertain important pathogenic || likely important pathogenic || important pathogenic
83
||'''high importance'''|| uncertain very important pathogenic || likely very important pathogenic || very important pathogenic 
84 61 Jason Bobe
85 64 Jason Bobe
Criteria for evidence:
86
 a. For no qualifier (ie, well-established): (1) at least 4 stars in either "Case/control evidence" or "Familial evidence" and (2) at least eight stars total
87
 a. For "likely": (1) at least 3 stars in either "Case/control evidence" or "Familial evidence" and (2) at least six stars total
88
 a. Otherwise "uncertain"
89
90
Criteria for importance (not used for benign and protective):
91
 a. For "very important": (1) at least 3 stars in severity and (2) at least 4 stars in either severity or treatability
92
 a. For "important": (1) at least 2 stars in severity and (2) at least 3 stars in either severity or treatability
93 65 Jason Bobe
 a. Otherwise no qualifier
94 39 Jason Bobe
95 19 Jason Bobe
When Genetests and/or the literature give multiple phenotypes for a variant, the impact should be reported for the most extreme condition and annotated as such in the ''short summary''. In the future we hope to list different phenotypes separately.
96
97
 === Inheritance Pattern === 
98
 a. Dominant
99
 a. Recessive
100
 a. Other: A defined form of inheritance that is neither dominant or recessive (e.g. modifier, co-dominant, incomplete penetrance). These variants will get prioritized due to their potential phenotypic affect should the additional factors be present.
101
 a. Undefined: Undefined in the literature.
102
 a. Unknown: The default value for all variants and all variants without literature.
103
104 22 Jason Bobe
 === Summary of published research, and additional commentary === 
105 1 Jason Bobe
 * Free text providing a comprehensive review of the variant including youngest age of onset, oldest age of onset and oldest asymptomatic individual. 
106 21 Jason Bobe
107 22 Jason Bobe
 === Allele Frequency === 
108 21 Jason Bobe
 * Automatically generated frequencies for the !HapMap Project, 1000 Genomes Project and the weighted average of the two.  Sub-population frequencies and homozygous/heterozygous break-downs are currently not shown. 
109
110
 === Publications === 
111
112
 * User-entered publications and user entered synopses of the relevant details from the publication. A short summary is also entered for each paper (as above).
113
 
114
 === Genomes ===  
115
116
 * Automatically generated list of all genomes from Trait-o-matic in which this variant is seen. Additionally, specific actions taken by each individual harboring the variant can be reported.
117
 
118
 === Other External References === 
119 13 Jason Bobe
These are automatically generated by web "robots":  
120 12 Jason Bobe
   a. dbSNP: The link to the dbSNP entry for this nucleotide position (for this nucleotide change?)
121
   a. Genetests: Link to all clinical laboratories performing diagnostic tests on this gene and the list of diseases that the labs are looking for.
122 21 Jason Bobe
   a. Web Search Results: A web search for this exact variant using the Yahoo search engine
123
124
 === Edit History ===
125 20 Jason Bobe
 * Automatically generated history of all page edits with the contributor's name.
126
127
 == To Do ==
128 3 Jason Bobe
 * [wiki:GET-Evidence/23andWe]
129 1 Jason Bobe
130
 == Suggestions == 
131
132
 * your suggestion here.